SLC16A12 and nonpapillary renal cell carcinoma: Previous studies have found that increased SLC16A12 expression correlates with improved survival rates in ccRCC (Mei et al., 2019; Hou and Liu, 2023), highlighting its potential as a prognostic biomarker and therapeutic target (Hou and Liu, 2023).